Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Addict Med ; 16(1): e40-e43, 2022.
Article in English | MEDLINE | ID: mdl-33560696

ABSTRACT

OBJECTIVES: The purpose of this study was to assess the feasibility and clinical impact of telemedicine-based opioid treatment with buprenorphine-naloxone following the Coronavirus disease 2019 pandemic. METHODS: Participants included in this retrospective analysis consisted of adult New York City residents with opioid use disorder eligible for enrollment in the NYC Health+Hospitals Virtual Buprenorphine Clinic between March and May 2020 (n = 78). Follow-up data were comprised of rates of retention in treatment at 2 months, referrals to community treatment, and induction-related events. RESULTS: During the initial 9 weeks of clinic operations, the clinic inducted 78 patients on to buprenorphine-naloxone and completed 252 visits. Patient referrals included non-NYC Health + Hospitals (n = 22, 28.2%) and NYC Health + Hospitals healthcare providers (n = 17, 21.8%), homeless shelter staff (n = 13, 16.7%), and the NYC Health + Hospitals jail reentry program in Rikers Island (n = 11, 14.1%). At 8 weeks, 42 patients remained in care (53.8%), 21 were referred to a community treatment program (26.9%), and 15 were lost to follow-up (19.2%). No patients were terminated from care due to disruptive behavior or suspicions of diversion or misuse of Buprenorphine. Adverse clinical outcomes were uncommon and included persistent withdrawal symptoms (n = 8, 4.3%) and one nonfatal opioid overdose (0.5%). CONCLUSIONS: Telemedicine-based opioid treatment and unobserved home induction on buprenorphine-naloxone offers a safe and feasible approach to expand the reach of opioid use disorder treatment, primary care, and behavioral health for a highly vulnerable urban population during an unprecedented natural disaster.


Subject(s)
Buprenorphine , COVID-19 , Opioid-Related Disorders , Telemedicine , Adult , Buprenorphine/therapeutic use , Hospitals, Public , Humans , Narcotic Antagonists/therapeutic use , New York City/epidemiology , Opiate Substitution Treatment , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/epidemiology , Pandemics , Retrospective Studies , SARS-CoV-2
2.
Am J Addict ; 29(4): 305-312, 2020 07.
Article in English | MEDLINE | ID: mdl-32187771

ABSTRACT

BACKGROUND AND OBJECTIVES: Addiction is increasingly considered a chronic, relapsing brain disease; however, many scholars still disagree with the brain disease model of addiction. We set out to provide evidence of attorneys' and physicians' beliefs regarding the model. First, we asked the following question: do attorneys and physicians affirm the full brain disease model, or its modified form, or do they believe that addiction is driven by deficits in self-control or moral weakness? Second, we evaluated the extent to which such beliefs correspond to attitudes toward individuals with substance use disorders (SUDs). METHODS: A questionnaire was sent to resident physicians (N = 301) and criminal defense attorneys (N = 483) practicing in the United States. It was comprised of (i) an attitudes measure, (ii) a measure regarding conceptions of addiction, and (iii) demographic questions. RESULTS: Attorneys were more likely to believe that individuals with SUDs had "practically no choice" about whether to seek and use, whereas physicians were more likely to believe that such individuals had "genuine choice." For both groups of participants, the rejection of the full brain disease model of addiction was associated with more negative attitudes toward individuals with SUDs. CONCLUSION AND SCIENTIFIC SIGNIFICANCE: These results represent an important advance, as past research has neglected attorneys' attitudes and is inconclusive regarding the manner in which beliefs about the brain disease model of addiction are related to attitudes toward individuals with SUDs. Educating practitioners regarding this relationship would raise awareness regarding when and to what extent stigma is likely to be present, which may in turn provide a foundation from which to address stigma. (Am J Addict 2020;00:00-00).


Subject(s)
Attitude , Behavior, Addictive/physiopathology , Brain Diseases/psychology , Lawyers , Physicians , Substance-Related Disorders/psychology , Culture , Female , Humans , Male , Middle Aged , Models, Theoretical , Social Perception , Surveys and Questionnaires , United States
3.
Behav Processes ; 83(3): 242-6, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19944132

ABSTRACT

Stereotyped motor behaviors are a common consequence of environmental restriction in a wide variety of species. Although environmental enrichment has been shown to substantially reduce stereotypy levels, the various components of enrichment have not been evaluated independently to determine which is responsible for this effect. Exercise, particularly voluntary wheel running, is a promising candidate based on several lines of behavioral and neurobiological evidence. To test the hypothesis that access to wheel running will reduce stereotyped motor behavior, we reared deer mice from weaning with continuous access to either a functional running wheel or a locked wheel. We assessed running behavior throughout this time period and stereotypy levels in a test context at 30 and 45 days post-weaning. We found that exercise did not significantly affect stereotypy level nor was there an association between wheel running and stereotypy. Thus, exercise alone, unlike environmental enrichment, does not prevent the development of stereotypy. These results have important implications for animal welfare.


Subject(s)
Physical Conditioning, Animal , Stereotyped Behavior , Analysis of Variance , Animals , Environment , Female , Housing, Animal , Male , Motor Activity , Peromyscus , Random Allocation , Time Factors , Volition
SELECTION OF CITATIONS
SEARCH DETAIL
...